1. In vivo restoration of laminin 5 β3 expression and function in junctional epidermolysis bullosa
- Author
-
Qun Lin, Paul A. Khavari, Xinjian Chen, Paul B. Robbins, Hongsheng Tian, and Julia B. Goodnough
- Subjects
Keratinocytes ,Genetic enhancement ,Genetic Vectors ,Human skin ,Gene delivery ,Junctional epidermolysis bullosa (medicine) ,Basement Membrane ,Viral vector ,Laminin ,medicine ,Humans ,Regeneration ,Cells, Cultured ,Cell Size ,Skin ,Basement membrane ,Multidisciplinary ,integumentary system ,biology ,Stem Cells ,Hemidesmosome ,Gene Transfer Techniques ,Cell Polarity ,Genetic Therapy ,Biological Sciences ,medicine.disease ,Kinetics ,medicine.anatomical_structure ,Immunology ,biology.protein ,Cancer research ,Epidermolysis Bullosa, Junctional ,Cell Adhesion Molecules ,Cell Division - Abstract
The blistering disorder, lethal junctional epidermolysis bullosa (JEB), can result from mutations in the LAMB3 gene, which encodes laminin 5 β3 (β3). Appropriate expression of LAMβ3 in JEB skin tissue could potentially ameliorate the symptoms of the underlying disease. To explore the utility of this therapeutic approach, primary keratinocytes from six unrelated JEB patients were transduced with a retroviral vector encoding β3 and used to regenerate human skin on severe combined immunodeficient (SCID) mice. Tissue regenerated from β3-transduced JEB keratinocytes produced phenotypically normal skin characterized by sustained β3 expression and the formation of hemidesmosomes. Additionally, β3 gene transfer corrected the distribution of a number of important basement membrane zone proteins including BPAG2, integrins β4/β1, and laminins α3/γ2. Skin produced from β3-negative (β3[−]) JEB cells mimicked the hallmarks of the disease state and did not exhibit any of the aforementioned traits. Therefore, by effecting therapeutic gene transfer to β3-deficient primary keratinocytes, it is possible to produce healthy, normal skin tissue in vivo . These data support the utility of gene therapy for JEB and highlight the potential for gene delivery in the treatment of human genetic skin disease.
- Published
- 2001